ATTAIN-1 trial results

Adults without diabetes who had obesity or overweight with a weight-related condition.

Foundayo

Phase: Phase 3
Follow-up: 72 weeks
Randomised: 3,127
Sponsor: Eli Lilly
Publication: New England Journal of Medicine · 2025

Double-blind, placebo-controlled. Treatment-regimen analysis. The trial used capsules with different strengths from the marketed tablets.

Mean body weight change at 72 weeks

Orforglipron 6 mg−7.5%
Orforglipron 12 mg−8.4%
Orforglipron 36 mg−11.2%
Placebo−2.1%

Mean body weight change at 72 weeks
Trial arm	Result
Orforglipron 6 mg	−7.5%
Orforglipron 12 mg	−8.4%
Orforglipron 36 mg	−11.2%
Placebo	−2.1%

Participants who lost at least 10% of body weight at week 72
Trial arm	Result
Orforglipron 6 mg	33.3%
Orforglipron 12 mg	40.0%
Orforglipron 36 mg	54.6%
Placebo	12.9%

Safety. Adverse events led 5.3–10.3% across the orforglipron groups and 2.7% of the placebo group to stop treatment. Gastrointestinal events were the most common.

Published paper PubMed abstract NCT05869903